A detailed history of Values First Advisors, Inc. transactions in Inozyme Pharma, Inc. stock. As of the latest transaction made, Values First Advisors, Inc. holds 14,695 shares of INZY stock, worth $44,231. This represents 0.04% of its overall portfolio holdings.

Number of Shares
14,695
Previous 17,067 13.9%
Holding current value
$44,231
Previous $76,000 -0.0%
% of portfolio
0.04%
Previous 0.05%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 23, 2024

SELL
$4.31 - $6.0 $10,223 - $14,232
-2,372 Reduced 13.9%
14,695 $76,000
Q2 2024

Jul 19, 2024

BUY
$4.33 - $7.31 $73,900 - $124,759
17,067 New
17,067 $76,000
Q4 2023

Jan 18, 2024

BUY
$2.71 - $4.5 $37,663 - $62,541
13,898 New
13,898 $59,000

Others Institutions Holding INZY

About Inozyme Pharma, Inc.


  • Ticker INZY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,145,700
  • Market Cap $121M
  • Description
  • Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...
More about INZY
Track This Portfolio

Track Values First Advisors, Inc. Portfolio

Follow Values First Advisors, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Values First Advisors, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Values First Advisors, Inc. with notifications on news.